Synthesis of cytarabine lipid drug conjugate for treatment of meningeal leukemia: Development, characterization and in vitro cell line studies

Journal of Biomedical Nanotechnology

Volumn 8, Issue 6, 2012, Pages 928-937

  Sharma, Pravin ^a   Dube, Brahmanand ^a   Sawant, Krutika ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Cytarabine; In vitro cytotoxicity; Leukemic EL 4 cell line; Lipid drug conjugate; Sustained release

Indexed keywords

CELL LINES; CYTARABINE; DRUG-CONJUGATES; IN-VITRO; SUSTAINED RELEASE;

CELL CULTURE; DISEASES; DRUG PRODUCTS; HYDROPHILICITY; NANOPARTICLES; STEARIC ACID; ZETA POTENTIAL;

CYTOTOXICITY;

CYTARABINE; LIPID DRUG CONJUGATE; NANOCONJUGATE; NANOPARTICLE; POLYSORBATE; POLYSORBATE 80; STEARIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; HYDROPHILICITY; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIC MENINGITIS; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; X RAY DIFFRACTION; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTARABINE; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; LEUKEMIA; LIPIDS; MENINGEAL NEOPLASMS; MICE; MODELS, CHEMICAL; PARTICLE SIZE; POLYSORBATES; STEARIC ACIDS;

EID: 84865324418     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1464     Document Type: Article

References (57)

1. S. L. Berg and D. G. Poplack, Treatment of meningeal malignancy. The Oncologist 1, 56 (1996).
2. A. M. Marmont, Leukemic meningitis in B-cell chronic lymphocytic leukemia. Blood 96, 776 (2000).
3. J. B. Aragon and J. A. Zujewski, CNS metastasis. Clin. Cancer Res. 13, 1644 (2007).
4. A. Beduneau, P. Saulnier, and J. P. Benoit, Active targeting of brain tumors using nanocarriers: Review. Biomaterials 28, 4947 (2007).
5. D. Pinkel and S. Woo, Prevention and treatment of meningeal leukemia in children. Blood 84, 355 (1994).
6. H. L. Wong, R. Bendayan, A. M. Rauth, Y. Li, and X. Y. Wu, Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Delivery Rev. 59, 491 (2007).
7. M. Muchow, P. Maincent, and R. H. Muller, Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev. Ind. Pharm. 34, 1394 (2008).
8. R. H. Müller, D. Ruhl, and S. A. Runge, Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int. J. Pharm. 144, 115 (1996).
9. S. Ali, A. R. Khan, M. U. Ahmad, P. Chen, S. Sheikh, and I. Ahmad, Synthesis and biological evaluation of gemcitabine-lipid conjugate. Bioorg. Med. Chem. Lett. 15, 2571 (2005).
10. A. Homma, H. Sato, A. Okamachi, T. Emura, T. Ishizawa, T. Kato, S. Matsuura, T. Sato, Y. Tamura, T. Higuchi, H. Watanabe, K. Kitamura, T. Asanuma, M. Yamazaki, H. Ikemi, T. Kitagawa, H. Morikawa, K. Ikeya, K. Maeda, K. Takahashi, N. Nohmi, M. Izutani, and R. Kanda, Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment. Bioorg. Med. Chem. Lett. 17, 4647 (2009).
11. J. X. Wang, X. Sun, and Z. R. Zhang, Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 54, 285 (2002).
12. O. Carsten, A. Gessner, W. Schröder, O. Kayser, and R. H. Müller, Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene - cytotoxicity testing and mouse serum adsorption. J. Controlled Release 96, 425 (2004).
13. A. E. Gulyaev, S. E. Gelperina, I. E. Skidan, A. S. Antopov, G. Y. Kivman, and J. Kreuter, Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16, 1564 (1999).
14. M. G. Torsten and R. H. Muller, Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. J. Drug Targeting 13, 179 (2005).
15. A. Gessner, O. Carsten, W. Schroder, O. Kayser, and R. H. Muller, The role of plasma proteins in brain targeting: Species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int. J. Pharm. 214, 87 (2001).
16. T. Xin-Hua, L. Xiao-Ning, W. Feng, F. Wei, H. Zhi-Chun, W. Peng, R. Lei, and D. Yi, Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. International Journal of Nanomedicine 445 (2011).
17. R. N. Alyautdin, V. E. Petrov, K. Langer, A. Berthold, D. A. Kharkevich, and J. Kreuter, Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14, 325 (1997).
18. S. Wangqiang, X. Changsheng, W. Huafang, and H. Yu, Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 3065 (2004).
19. J. Kreuter, Nanoparticulate systems for brain delivery of drugs. Adv. Drug Delivery Rev. 47, 65 (2001).
20. K. S. Yadav and K. K. Sawant, Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. AAPS Pharm. Sci. Tech. 11, 1456 (2010).
21. R. Parasole, G. Menna, N. Marra, F. Petruzziello, F. Locatelli, M. A. Argia, A. Misuraca, S. Buffardi, A. C. Merlone, and V. Poggi, Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: Experience of two pediatric institutions. Leuk. Lymphoma 49, 1553 (2008).
22. T. Yamauchi, E. Negoro, S. Kishi, K. Takagi, A. Yoshida, Y. Urasaki, H. Iwasaki, and T. Ueda, Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem. Pharmacol. 77, 1780 (2009).
23. R. L. Capizzi, J. C. White, B. L. Powell, and F. Perrino, Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin. Hematol. 28, 54 (1991).
24. M. Burk, A. Heyll, M. Arning, M. Volmer, K. Fartash, and W. Schneider, Pharmacokinetics of high-dose cytarabine and its deamination product-a reappraisal. Leuk. Lymphoma 27, 321 (1997).
25. E. Cros, L. Jordheim, C. Dumontet, and C. M. Galmarini, Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk. Lymphoma 45, 1123 (2004).
26. M. Menger and M. J. Rourk, Synthesis and reactivity of 5-fluorouracil/cytarabine mutual prodrugs. J. Org. Chem. 62, 9083 (1997).
27. S. C. Tobias and R. F. Borch, Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Molecular Pharmaceutics 1, 112 (2004).
28. G. S. Maria, O. Sara, C. G. Maria, R. Flavio, C. Maurizio, and C. Francesco, Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. Int. J. Pharm. 406, 69 (2011).
29. M. Kluge and H. Schott, Cytarabine derivatives, the preparation and use thereof, US Patents, Application Number: 08/335090, filing date 11, July (1994).
30. B. Knut, B. Jan, L. S. Marit, M. Finn, M. Marita, D. C. Erik, and F. Oystein, Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and S. C. human tumor xenograft models. Cancer Research 59, 2944 (1999).
31. E. K. Ryu, R. J. Ross, T. Matsushita, M. MacCoss, C. I. Hong, and C. R. West, Phospholipid-nucleoside conjugates. Syntheses and preliminary biological evaluation of 1-beta-Darabinofuranosylcytosine 5′-monophosphate-L-1,2- dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2- diacylglycerols. J. Med. Chem. 25, 1322 (1982).
32. C. I. Hong, R. J. Bernacki, S. W. Hui, Y. Rustum, and C. R. West, Formulation, stability, and antitumor activity of 1-beta- D- arabinofuranosylcytosine conjugate of thioether phospholipid. Cancer Research 50, 4401 (1990).
33. B. S. Chhikara, D. Mandal, and K. Parang, Synthesis and evaluation of fatty acyl ester derivatives of cytarabine as anti-leukemia agents. European Journal of Medicinal Chemistry 45, 4601 (2010).
34. N. Denora, V. Laquintana, A. Trapani, A. Lopedota, A. Latrofa, J. M. Gallo, and G. Trapani, Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential. Molecular Pharmaceutics 6, 2255 (2010).
35. S. C. Bhupender and P. Keykavous, Development of cytarabine pro-drugs and delivery systems for leukemia treatment. Expert Opinion on Drug Delivery 7, 1399 (2010).
36. G. Stela and I. Esther, Conjugates for cancer therapy and diagnosis, Patent application number: 20110275590; Publication date: 11, October (2011).
37. C. Dan-Qi, W. Xin, C. Lin, H. Jin-Xue, M. Ze-Hong, and S. Jing-Kang, Novel liver-specific cholic acid-cytarabine conjugates with potent antitumor activities: Synthesis and biological characterization. Acta Pharmacologica Sinica 32, 664 (2011).
38. P. Sharma, B. Dube, and K. Sawant, Development and evaluation of nanostructured lipid carriers of cytarabine for treatment of meningeal leukemia, J. Nanosci. Nanotechnol. 11, 6676 (2011).
39. G. T. Hermanson (ed.), Bioconjugate techniques, Thermo Fisher Scientific, 2nd edn., Rockford, Illinois, USA (2008).
40. N. Nakajima and Y. Ikada, Mechanism of amide formation by carbodiimides for bioconjugation in aqueous media. Bioconjugate Chem. 6, 123 (1995).
41. R. Pignatello, G. Spampinato, V. Sorrenti, C. Giacomod, L. Vicari, J. McGuire, C. Russell, G. Puglisi, and I. Toth, Lipophilic methotrexate conjugates with antitumor activity. Eur. J. Pharm. Sci. 10, 237 (2000).
42. R. S. R. Murthy, N. Subramanian, and A. Yajnik, Artificial neural network as an alternative to multiple regression analysis in optimizing formulation parameters of cytarabine liposomes. AAPS Pharm. Sci. Tech. 5, 1 (2004).
43. M. A. Schubert and C. C. Goymann, Solvent injection as a new approach for manufacturing lipid nanoparticles - evaluation of the method and process parameters. Eur. J. Pharm. Biopharm. 55, 125 (2003).
44. Boyer, S. Erion, and D. Mark, Cytarabine monophosphate prodrugs, U. S. Patent 7553826, June (2009).
45. L. Ferreira, M. M. Vidal, and M. H. Gil, Evaluation of poly(2- hydroxyethyl methacrylate) gels as drug delivery systems at different pH value. Int. J. Pharm. 194, 169 (2000).
46. S. Ren, S. Yang, Y. Zhao, T. Yu, and X. Xiao, Preparation and characterization of an ultrahydrophobic surface based on a stearic acid self-assembled monolayer over polyethyleneimine thin films. Surf. Sci. 546, 64 (2003).
47. B. Wen, Y. Sun, Y. Xu, J. Sun, X. Liu, Y. Wang, T. Zhang, and Z. He, Pharmacokinetic characteristics of the cytarabine prodrug, ilecytarabine, after intravenous and oral administration to rats. A. J. Pharm. Sci. 3, 200 (2008).
48. G. Knothe and J. A. Kenar, Determination of the fatty acid profile by 1H-NMR spectroscopy. Eur. J. Lipid Sci. Technol. 106, 88 (2004).
49. V. Jenning, A. Thunemann, and S. Gohla, Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 199, 167 (2000).
50. A. Sari, M. Akcay, M. Soylak, and A. Onal, Polymer - stearic acid blends as form-stable phase change material for thermal energy storage. J. Sci. Ind. Res. 64, 991 (2005).
51. A. Dicko, S. Kwak, A. A. Frazier, L. D. Mayer, and B. D. Liboiron, Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int. J. Pharm. 391, 248 (2010).
52. S. C. Yang, L. F. Lu, J. B. Zhu, and W. L. Bing, Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Controlled Release 59, 299 (1999).
53. R. I. Freshney (ed.), MTT-based cytotoxicity assay, Culture of Animal Cells: A Manual of Basic Technique, 4th edn., Wiley Publication, USA (2005).
54. R. R. Zhu, L. L. Qin, M. Wang, S. M. Wu, S. L. Wang, R. Zhang, and Z. X. Liu, Preparation, characterization, and anti-tumor property of podophyllotoxin-loaded solid lipid nanoparticles. Nanotechnology 20, 1 (2009).
55. V. Venkateswarlu and K. Manjunath, Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Controlled Release 95, 627 (2004).
56. V. Bebezin, N. F. Kazanskaya, A. A. Klyosov, and V. K. Svedas, The mechanism of the α-chemotrypsin and trypsin-catalyzed hydrolysis of amides: Evidence for the participation of the active serine in the amidase activity of trypsin. Eur. J. Biochem. 38, 529 (1973).
57. B. A. Chabner and D. L. Longo (eds.), Cytidine Analogs, Cancer Chemotherapy and Biotherapy, Lippincott-Raven Publishers, Philadelphia (1996).